Andrographis Ingredient Granted EU Patent for Possible Alzheimer’s Disease Benefit

For years, researchers have been exploring diverse avenues for an effective treatment against the debilitating Alzheimer's disease. An encouraging breakthrough comes as HP Ingredients, a Bradenton, FL-based company, secures a European Union (EU) patent for NeuroActin, their cognitive-health ingredient derived from Andrographis paniculata, a plant known for its diverse medicinal properties.

What Makes NeuroActin a Standout?

NeuroActin is a specific extract containing andrographolide, a labdane diterpenoid isolated from the stems and leaves of Andrographis paniculata. This compound's potential in the treatment of Alzheimer’s disease dementia has been recognized in the EU patent, suggesting a therapeutically effective daily oral dosage of one to four mg per kg of body weight.

Promising Evidence from Animal Studies

HP Ingredients' application for the patent was reinforced by their own clinical studies, which have shown promising results for NeuroActin's effectiveness against Alzheimer's. In a mouse model of Alzheimer's disease, andrographolide not only prevented but also reversed neuropathy. It was found to enhance mice's spatial memory function, decrease amyloid β-peptide (Aβ) plaques in the brain – a signature of Alzheimer's – and boost field excitatory post-synaptic potentials. "Our results suggest that andrographolide might be used in a potential preventative and reversible therapy during the progression state of Alzheimer's disease," noted the authors of the study.

A Step Forward, Despite FDA Restrictions

Although FDA regulations currently prevent the company from marketing NeuroActin explicitly for Alzheimer's disease treatment, the EU patent acknowledges NeuroActin's potential in cognitive support. Annie Eng, CEO of HP Ingredients, explains in a press release, "This is significant news because it demonstrates the increasingly sophisticated technological research can be accumulated to make specific claims. Although we recognize that the FDA prohibits marketing NeuroActin for any disease state, this EU patent is encouraging as it supports that NeuroActin is an effective supplement for supporting healthy brain structure and function as well as cognitive acuity and memory."

As we traverse the complex landscape of Alzheimer's disease, the EU patent of NeuroActin paves a promising path. The ingredient's potential not only lies in improving cognitive health but also potentially in preventing and reversing some aspects of Alzheimer's disease – a possibility that continues to inspire researchers to dive deeper.

Keywords: NeuroActin, Alzheimer's Disease, Andrographolide, Andrographis Paniculata, HP Ingredients, Cognitive Health, EU Patent, FDA Regulations, Amyloid β-Peptide (Aβ) Plaques

Source: https://www.nutritionaloutlook.com/view/andrographis-ingredient-granted-eu-patent-possible-alzheimers-disease-benefit